番茄社区app

Trial from China provides proof-of-concept for stroke risk reduction in symptomatic cases

Continued OAC failed to meet noninferiority in POPular PAUSE TAVI

Recent developments of interest in cardiovascular medicine

Trial paints a fuller picture of risk-benefit in complex patient population

Fear shouldn't drive medical intervention

Afib, hypertension, and others get updates with simplifications

More conclusive evidence for benefits on Afib burden, QoL

Bleeding reduced -- without risk of ischemic events -- versus dual antithrombotic in Korean trial

NOTION-3 trial informs care for those with severe AS and stable CAD

RESHAPE-HF2 has provocative implications for a wider pool of TEER candidates

Also in TTHealthWatch: myocarditis after COVID vaccination

Either choice is "acceptable" based on randomized study

And two aren't in the standard cardiovascular risk prediction tool

No benefit to beta-blocker interruption among MI survivors using them for secondary prevention